Kevin M. Shannon - Publications

Affiliations: 
Biomedical Sciences University of California, San Francisco, San Francisco, CA 
Area:
Cell Biology, Molecular Biology

94 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, et al. KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Reports. PMID 26854235 DOI: 10.1016/J.Celrep.2016.01.034  0.6
2016 White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ. KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nature Communications. 7: 10647. PMID 26854029 DOI: 10.1038/Ncomms10647  0.6
2016 Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey J, Bollag G, Shannon K, Walter N, et al. Abstract LB-008: KRAS engages AGO2 to enhance cellular transformation Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-008  0.6
2015 Wong JC, Weinfurtner KM, Alzamora MD, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, ... Shannon K, et al. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 4. PMID 26193121 DOI: 10.7554/Elife.07839  0.48
2015 Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics. 47: 539-43. PMID 25822087 DOI: 10.1038/Ng.3251  0.48
2015 Shankar S, Malik R, Kothari V, Hosono Y, Pitchiaya S, Kalyana-Sundaram S, Yocum A, Escara-Wilke J, Gundlapalli H, Chinnaswamy K, Shuler M, Poliakov A, Wang X, Krishnan V, White Y, ... ... Shannon K, et al. Abstract LB-058: Novel interactions of the RAS oncoprotein Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-058  0.6
2014 Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 124: 3947-55. PMID 25361812 DOI: 10.1182/Blood-2014-05-574582  0.48
2014 Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. Blood. 124: 3274-83. PMID 25316678 DOI: 10.1182/Blood-2013-08-521708  0.48
2014 Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature. 513: 512-6. PMID 25043004 DOI: 10.1038/Nature13495  0.48
2014 Shannon K, Hermiston M. A(nother) RAF mutation in LCH Blood. 123: 3063-3065. PMID 24832939 DOI: 10.1182/Blood-2014-04-565481  0.48
2014 Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia Cancer Cell. 25: 652-665. PMID 24794707 DOI: 10.1016/J.Ccr.2014.03.016  0.48
2014 Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML. Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood. 123: 1426-7. PMID 24578498 DOI: 10.1182/Blood-2013-11-531079  0.48
2014 North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD. Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. Bmc Cancer. 14: 6. PMID 24386979 DOI: 10.1186/1471-2407-14-6  0.48
2014 Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 490-8. PMID 24178622 DOI: 10.1158/1078-0432.Ccr-13-1311  0.48
2013 Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, ... Shannon K, et al. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Science Signaling. 6: ra105. PMID 24300897 DOI: 10.1126/Scisignal.2004125  0.48
2013 Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature. 504: 143-7. PMID 24284627 DOI: 10.1038/Nature12830  0.48
2013 Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 122: 1610-20. PMID 23818547 DOI: 10.1182/Blood-2013-01-481457  0.48
2013 Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood. 121: 4884-93. PMID 23637129 DOI: 10.1182/Blood-2012-05-432252  0.48
2013 Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, et al. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Science Signaling. 6: ra21. PMID 23532335 DOI: 10.1126/Scisignal.2003848  0.48
2013 Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. The Journal of Clinical Investigation. 123: 335-9. PMID 23221337 DOI: 10.1172/Jci63193  0.48
2012 Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 120: 3397-406. PMID 22898602 DOI: 10.1182/Blood-2012-05-378596  0.48
2012 Shah NP, Shannon K. Advancing the STATus of MPN pathogenesis Blood. 119: 3374-3376. PMID 22500049 DOI: 10.1182/Blood-2012-02-406611  0.48
2012 Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood. 119: 1032-5. PMID 22144181 DOI: 10.1182/Blood-2011-06-358960  0.48
2011 Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, et al. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 117: 4253-61. PMID 21398220 DOI: 10.1182/Blood-2010-11-319517  0.48
2011 Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Research. 71: 106-15. PMID 21199799 DOI: 10.1158/0008-5472.Can-10-2732  0.48
2011 Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 117: 2022-32. PMID 21163920 DOI: 10.1182/Blood-2010-04-280750  0.48
2011 Shannon K, Li Q. Oncogenic Ras scales the ALPS Blood. 117: 2747-2748. DOI: 10.1182/Blood-2010-12-320721  0.48
2010 Shannon K, Armstrong SA. Genetics, epigenetics, and leukemia. The New England Journal of Medicine. 363: 2460-1. PMID 21067376 DOI: 10.1056/Nejme1012071  0.48
2010 Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. The Journal of Experimental Medicine. 207: 2581-94. PMID 21059853 DOI: 10.1084/Jem.20091071  0.48
2010 Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes & Development. 24: 1389-402. PMID 20595231 DOI: 10.1101/Gad.1940710  0.48
2010 Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, Alzamora P, Kogan SC, Akagi K, Wolff L, Le Beau MM, Killeen N, Shannon K. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. Blood. 115: 4524-32. PMID 20233966 DOI: 10.1182/Blood-2009-07-232504  0.48
2010 Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proceedings of the National Academy of Sciences of the United States of America. 107: 5106-11. PMID 20194733 DOI: 10.1073/Pnas.1001064107  0.48
2010 Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, et al. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. American Journal of Medical Genetics. Part A. 152: 4-24. PMID 20014119 DOI: 10.1002/Ajmg.A.33183  0.48
2010 Ward AF, Shieh A, Harding-Theobald ER, Bollag G, Shannon K. Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis Blood. 116: 4200-4200. DOI: 10.1182/Blood.V116.21.4200.4200  0.6
2009 Søvik O, Schubbert S, Houge G, Steine SJ, Norgård G, Engelsen B, Njølstad PR, Shannon K, Molven A. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. Bmj Case Reports. 2009. PMID 21686750 DOI: 10.1136/Bcr.07.2008.0550  0.6
2009 Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, ... ... Shannon K, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 461: 411-4. PMID 19727076 DOI: 10.1038/Nature08279  0.48
2009 Shannon K, Loh M. Cancer: More than kin and less than kind Nature. 460: 804-807. PMID 19675635 DOI: 10.1038/460804A  0.48
2009 Braun BS, Shannon K. The SPS Affair: A Complex Tale of Illicit Proliferation Cancer Cell. 16: 87-88. PMID 19647218 DOI: 10.1016/J.Ccr.2009.07.005  0.48
2009 Zhang Y, Wong J, Klinger M, Tran MT, Shannon KM, Killeen N. MLL5 contributes to hematopoietic stem cell fitness and homeostasis. Blood. 113: 1455-63. PMID 18818388 DOI: 10.1182/Blood-2008-05-159905  0.48
2008 Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 14: 335-43. PMID 18835035 DOI: 10.1016/J.Ccr.2008.08.014  0.48
2008 Braun BS, Shannon K. Targeting ras in myeloid leukemias Clinical Cancer Research. 14: 2249-2252. PMID 18413813 DOI: 10.1158/1078-0432.Ccr-07-1005  0.48
2008 Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics. 40: 600-8. PMID 18372904 DOI: 10.1038/Ng.115  0.48
2008 Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 111: 1044-53. PMID 18000167 DOI: 10.1182/Blood-2007-04-084293  0.48
2008 Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Human Mutation. 29: 232-9. PMID 17979197 DOI: 10.1002/Humu.20616  0.6
2007 Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A, Shannon K. Biochemical and functional characterization of germ line KRAS mutations. Molecular and Cellular Biology. 27: 7765-70. PMID 17875937 DOI: 10.1128/Mcb.00965-07  0.6
2007 Diaz-Flores E, Shannon K. Targeting oncogenic Ras Genes and Development. 21: 1989-1992. PMID 17699748 DOI: 10.1101/Gad.1587907  0.48
2007 Søvik O, Schubbert S, Houge G, Steine SJ, Norgård G, Engelsen B, Njølstad PR, Shannon K, Molven A. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. Journal of Medical Genetics. 44: e84. PMID 17601930 DOI: 10.1136/Jmg.2007.049361  0.6
2007 Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer Nature Reviews Cancer. 7: 295-308. PMID 17384584 DOI: 10.1038/Nrc2109  0.48
2007 Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog Current Opinion in Genetics and Development. 17: 15-22. PMID 17208427 DOI: 10.1016/J.Gde.2006.12.004  0.48
2007 Shannon K, Bollag G. Sending out an SOS Nature Genetics. 39: 8-9. PMID 17192780 DOI: 10.1038/Ng0107-8  0.48
2007 Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 109: 3945-52. PMID 17192389 DOI: 10.1182/Blood-2006-09-047530  0.48
2007 Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 109: 1687-91. PMID 17090653 DOI: 10.1182/Blood-2006-05-025395  0.48
2007 Schubbert S, Shannon K, Bollag G. Erratum: Hyperactive Ras in developmental disorders and cancer Nature Reviews Cancer. 7: 564-564. DOI: 10.1038/Nrc2175  0.6
2006 Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle (Georgetown, Tex.). 5: 1607-11. PMID 16921267 DOI: 10.4161/Cc.5.15.3128  0.6
2006 Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 108: 2041-4. PMID 16720837 DOI: 10.1182/Blood-2006-01-013490  0.48
2006 Gutmann DH, Hunter-Schaedle K, Shannon KM. Harnessing preclinical mouse models to inform human clinical cancer trials. The Journal of Clinical Investigation. 116: 847-52. PMID 16585951 DOI: 10.1172/Jci28271  0.48
2006 Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, Neuberg DS, Shannon KM, Sallan SE, Gilliland DG. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 107: 4508-13. PMID 16493009 DOI: 10.1182/Blood-2005-08-3451  0.48
2006 Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, ... ... Shannon K, et al. Germline KRAS mutations cause Noonan syndrome. Nature Genetics. 38: 331-6. PMID 16474405 DOI: 10.1038/Ng1748  0.48
2006 Schubbert S, Sovik O, Bollag G, Nguyen H, Rowe SL, Kratz C, Zenker MM, Niemeyer CM, Molven A, Shannon K. Biochemical and Functional Analysis of Germline KRAS Mutations That Cause Disorders of the Noonan Syndrome Spectrum. Blood. 108: 1431-1431. DOI: 10.1182/Blood.V108.11.1431.1431  0.6
2006 Shannon K. Reconsidering how we treat severe congenital neutropenia Blood. 107: 4575-4576. DOI: 10.1182/Blood-2006-04-012146  0.48
2006 Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, Burgt Ivd, Musante L, Kalscheuer V, Wehner L, Nguyen H, West B, Zhang KYJ, Sistermans E, Rauch A, ... ... Shannon K, et al. Corrigendum: Germline KRAS mutations cause Noonan syndrome Nature Genetics. 38: 598. DOI: 10.1038/Ng0506-598  0.6
2006 Kratz CP, Schubbert S, Zenker M, Böll S, Bollag G, Niemeyer CM, Shannon KM. Noonan syndrome and juvenile myelomonocytic leukemia: Different diseases caused by deregulation of identical pathways Leukemia Research. 30. DOI: 10.1016/S0145-2126(06)80010-X  0.6
2005 Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 8: 337-48. PMID 16226708 DOI: 10.1016/J.Ccr.2005.08.011  0.48
2005 Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 106: 1183-8. PMID 15886328 DOI: 10.1182/Blood-2004-10-3821  0.48
2005 Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP, Emerling BM, Green ED, Le Beau MM, Shannon KM. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics. 85: 600-7. PMID 15820312 DOI: 10.1016/J.Ygeno.2005.01.013  0.48
2005 Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood. 106: 311-7. PMID 15761018 DOI: 10.1182/Blood-2004-11-4207  0.48
2005 Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Burgt Ivd, Musante L, Nguyen H, West B, Bollag G, Niemeyer CM, Shannon KM, Kratz CP. Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth. Blood. 106: 1602-1602. DOI: 10.1182/Blood.V106.11.1602.1602  0.6
2004 Braun BS, Shannon K. The sum is greater than the FGFR1 partner Cancer Cell. 5: 203-204. PMID 15050910 DOI: 10.1016/S1535-6108(04)00060-1  0.48
2004 Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America. 101: 597-602. PMID 14699048 DOI: 10.1073/Pnas.0307203101  0.48
2004 Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, ... Shannon KM, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 103: 2325-31. PMID 14644997 DOI: 10.1182/Blood-2003-09-3287  0.6
2003 Kratz CP, Antonietti L, Shannon KM, Dole MG, Friebert SE. Acute myeloid leukemia associated with t(8;21) or trisomy 8 in children with neurofibromatosis, type 1. Journal of Pediatric Hematology/Oncology. 25: 343. PMID 12679655 DOI: 10.1097/00043426-200304000-00018  0.48
2003 Weiss B, Shannon K. Mouse cancer models as a platform for performing preclinical therapeutic trials Current Opinion in Genetics and Development. 13: 84-89. PMID 12573440 DOI: 10.1016/S0959-437X(02)00016-3  0.48
2003 McCormick F, Shannon KM. Oncogenes and cell proliferation - Insights from inherited predispositions and mouse models: Editorial overview Current Opinion in Genetics and Development. 13: 3-5. DOI: 10.1016/S0959-437X(03)00003-0  0.48
2002 Shannon KM. Resistance in the land of molecular cancer therapeutics Cancer Cell. 2: 99-102. PMID 12204529 DOI: 10.1016/S1535-6108(02)00101-0  0.48
2002 Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene. 21: 4849-54. PMID 12101424 DOI: 10.1038/Sj.Onc.1205615  0.48
2002 Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochimica Et Biophysica Acta. 1602: 23-45. PMID 11960693 DOI: 10.1016/S0304-419X(01)00041-5  0.6
2002 Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Le Beau MM, Shannon KM. Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood. 99: 372-4. PMID 11756194 DOI: 10.1182/Blood.V99.1.372  0.48
2001 Banerjee A, Shannon KM. Leukemic transformation in patients with severe congenital neutropenia Journal of Pediatric Hematology/Oncology. 23: 487-495. PMID 11878775 DOI: 10.1097/00043426-200111000-00005  0.48
2001 Kratz CP, Emerling BM, Donovan S, Laig-Webster M, Taylor BR, Thompson P, Jensen S, Banerjee A, Bonifas J, Makalowski W, Green ED, Le Beau MM, Shannon KM. Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies. Genomics. 77: 171-80. PMID 11597142 DOI: 10.1006/Geno.2001.6636  0.48
2001 Shannon KM, Le Beau MM, Largaespada DA, Killeen N. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse Seminars in Cancer Biology. 11: 191-199. PMID 11407944 DOI: 10.1006/Scbi.2001.0372  0.48
2000 Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo Journal of Experimental Medicine. 191: 181-187. PMID 10620616 DOI: 10.1084/Jem.191.1.181  0.48
1999 Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. American Journal of Medical Genetics. 89: 14-22. PMID 10469432 DOI: 10.1002/(Sici)1096-8628(19990326)89:1<14::Aid-Ajmg5>3.0.Co;2-4  0.6
1998 Shannon K. Genetic predispositions and childhood cancer Environmental Health Perspectives. 106: 801-806. PMID 9646040 DOI: 10.1289/Ehp.98106801  0.48
1998 Frenck RW, Blackburn EH, Shannon KM. The rate of telomere sequence loss in human leukocytes varies with age Proceedings of the National Academy of Sciences of the United States of America. 95: 5607-5610. PMID 9576930 DOI: 10.1073/Pnas.95.10.5607  0.48
1997 Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. The New England Journal of Medicine. 336: 1713-20. PMID 9180088 DOI: 10.1056/Nejm199706123362404  0.48
1996 Gutmann DH, Gurney JG, Shannon KM, Zvulunov A. Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia [4] Archives of Dermatology. 132: 1390-1391. PMID 8915325 DOI: 10.1001/Archderm.132.11.1390  0.48
1996 Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. Erratum: Corrigendum: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells Nature Genetics. 12: 458-458. DOI: 10.1038/Ng0496-458C  0.6
1995 Shannon K. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis Current Opinion in Hematology. 2: 305-308. PMID 9372012 DOI: 10.1097/00062752-199502040-00011  0.48
1993 Kobayashi H, Espinosa R, Thirman MJ, Fernald AA, Shannon K, Diaz MO, Le Beau MM, Rowley JD. Do terminal deletions of 11q23 exist? Identification of undetected translocations with fluorescence in situ hybridization. Genes, Chromosomes & Cancer. 7: 204-8. PMID 7692945 DOI: 10.1002/Gcc.2870070404  0.48
1992 Shannon KM, Turhan AG, Rogers PC, Kan YW. Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7. Genomics. 14: 121-5. PMID 1358790 DOI: 10.1016/S0888-7543(05)80293-9  0.48
1990 George JW, Bracco CA, Shannon KM, Davis GJ, Smith IL, Phibbs RH, Hendrickx AG. Age-related differences in erythropoietic response to recombinant human erythropoietin: comparison in adult and infant rhesus monkeys. Pediatric Research. 28: 567-71. PMID 2284151 DOI: 10.1203/00006450-199012000-00003  0.48
1990 Shannon KM. Anemia of prematurity: Progress and prospects Journal of Pediatric Hematology/Oncology. 12: 14-20. PMID 2178457 DOI: 10.1097/00043426-199021000-00004  0.48
1989 Phibbs RH, Shannon K, Mentzer WC. Rationale for using recombinant human erythropoietin to treat the anemia of prematurity Contributions to Nephrology. 76: 324-328; discussion . PMID 2684531 DOI: 10.1159/000417909  0.48
1985 Shannon KM, Ammann AJ. Acquired immune deficiency syndrome in childhood The Journal of Pediatrics. 106: 332-342. PMID 2982008 DOI: 10.1016/S0022-3476(85)80320-6  0.48
Show low-probability matches.